¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"active form"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • balanced form
    ±ÕÇüÇü(гû¬û¡).
  • band form =stab cell
    °£»óÈ£Áß±¸
  • bell form
    Á¾Çü(̴̡).
  • bilinear form
    ½ÖÀÏÂ÷Çü½Ä(ËâËö̴̤ Ëà).
  • biphasic wave form
    ¾ç¸é ŽÃËÀÚ ÀÌ»ó¼º ÆÄÇü(廨ü÷®õºí­ì¶ßÈàõ÷îû¡).
  • box form
    »óÇü¿Íµ¿(ßÕû¡èÀ÷Ó)ÀÇ.
  • chemical form
    È­ÇÐÀû Çü»ó<ÇüÅÂ
  • color form sorting test
    »öäÇüÅÂ(ßäóôû¡÷¾)Ã߸®±â °Ë»ç(ËþÞÛ)
  • consent form
    µ¿ÀǼ­ Çü½Ä(ÔÒëòßö úýãÒ)
  • corrosion form
    ºÎ½ÄÇü(ݯãÚúþ).
  • crescent form
    ¹Ý´ÞÇü, ¹Ý¿ùü, ¹Ý¿ùÇü.
  • developmental form
    ¹ß´ÞÇü.
  • developmental form
    ¹ßÀ°Çü
  • distal form
    ¸»´ÜÇü(ØÇÓ®úþ).
  • enol form
    ¿¡³îÇü(¡­û¡).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • active translocation
    Ȱ¼ºÀüÀ§ (üÀàõï®êÈ)
  • active transport
    ´Éµ¿¼ö¼Û (ÒöÔÑâÃáê)
  • flexible active site
    °¡º¯(ʦܨ) Ȱ¼º(üÀàõ)ÀÚ¸®
  • gradient-coupled active transport
    ±¸¹è(ÎþÛÕ) ¦Áø ´Éµ¿¼ö¼Û(ÒöÔÑâÃáê)
  • primary active transport
    ÀÏÂ÷ ´Éµ¿¼ö¼Û(ìéó­ÒöÔÑâÃáê)
  • secondary active transport
    ÀÌÂ÷ ´Éµ¿¼ö¼Û(ì£ó­ÒöÔÑâÃáê)
  • surface-active agent
    Ç¥¸éȰ¼ºÁ¦ (øúØüüÀàõð¥)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
FADH2 reduced form of flavin adenine dinucleotide
FMNH, FMNH2 reduced form of flavin mononucleotide
form formula
FPH2 reduced form of flavin phosphate
F-SP special form [Lat. forma specialis]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
GST-P+ glutathione S-transferase placental form positive
iNOS inducible form of .NO synthase
iNOS inducible form of NOS
iNOS inducible form of nitric oxide synthase
sCD14 soluble form of CD14
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • liquid form
    ¾×ü »óÅÂ
    ¹°À̳ª ±â¸§°ú °°ÀÌ ÀÚÀ¯·ÎÀÌ À¯µ¿ÇÏ¿© ¿ë±âÀÇ ¸ð¾ç¿¡ µû¶ó ±× ¸ð¾çÀÌ º¯Çϸç ÀÏÁ¤ÇÑ ÇüŸ¦ °¡ÁöÁö ¾Ê°í ¾ÐÃàÇØµµ °ÅÀÇ ºÎÇǰ¡ º¯ÇÏÁö ¾Ê´Â ¹°Áú. Á¤È®È÷´Â ¾×ü »óŶó°í ÇÑ´Ù. ¼ö¸¹Àº ¹°Áú °¡¿îµ¥ »ó¿Â, »ó¾Ð¿¡¼­ ÀÌ¿Í °°Àº »óŸ¦ °¡Áö´Â °ÍÀº ºñ±³Àû ÀûÀ¸³ª, Àû´çÇÑ ¿Âµµ¿Í ¾Ð·ÂÀÇ Á¶°ÇÀÌ °®Ãß¾îÁö¸é °ÅÀÇ ¸ðµç ¹°ÁúÀÌ ¾×ü·Î º¯ÇÒ ¼ö ÀÖÀ¸¸ç, ¹Ý´ë·Î ¾×üµµ ´Ù½Ã ±âü³ª °íü·Î º¯ÇÒ ¼ö ÀÖ´Ù. Áï, ¾×ü¶ó´Â °ÍÀº ¹°Áú¿¡ °íÀ¯ÇÑ ¼ºÁúÀÌ ¾Æ´Ï¶ó Á¶°Ç¿¡ µû¶ó¼­ ±âü·Îµµ °íü·Îµµ º¯ÇÒ ¼ö ÀÖ´Â ¹°ÁúÀÇ Á¸Àç »óÅÂÀÇ Çϳª¿¡ ºÒ°úÇÏ´Ù. ÀÌ·± ¶æ¿¡¼­ °íü»ó, ±âü»ó¿¡ ´ëÇØ¼­ ¾×ü»óÀ̶ó°í ÇÏ´Â °æ¿ìµµ ÀÖ´Ù. ¶ÇÇÑ ÇϳªÀÇ ¹°ÁúÀÌ °íü¿¡¼­ ¾×ü·Î º¯È­ÇÏ´Â Çö»óÀ» À¶ÇØ, ¾×ü¸é¿¡¼­ ±âÈ­ÇÏ´Â °ÍÀ» Áõ¹ßÀ̶ó°í Çϳª, ±âÈ­´Â ¾×ü ³»ºÎ¿¡¼­µµ ÀϾ¸ç, ¾×ü°¡ Àü¸éÀûÀ¸·Î ±âü·Î º¯ÇÏ´Â Çö»óÀ» ºñµîÀ̶ó°í ÇÑ´Ù. ÀÏÁ¤ÇÑ ¾Ð·ÂÇÏ¿¡¼­ÀÇ
  • localized form
    ±¹¼Ò Çü
  • marginal form
    ¿Ü¿¬ ÇüÅÂ, º¯¿¬ ÇüÅÂ
  • mixed form
    È¥ÇÕ Çü
  • occlusal form
    ±³ÇÕ ÇüÅÂ
    Ä¡¾Æ³ª Ä¡¿­ÀÇ ±³ÇÕ¸éÀÇ ÇüÅÂ.
  • outline form of cavity
    ¿Íµ¿ ¿ÜÇü
    ¿Íµ¿ÀÇ ÇüÅ¿¡´Â ¿Íµ¿ ¿ÜÇü, À¯Áö ÇüÅÂ, ÀúÇ× ÇüÅÂ, ÆíÀÇ ÇüÅÂ¿Í °°ÀÌ 4Á¾·ù°¡ Àִµ¥ ¿Íµ¿ ¿ÜÇüÀ̶õ ¿Íµ¿ Çü¼º¿¡ À־ °¡Àå ±âº»ÀÌ µÇ´Â °ÍÀ¸·Î ¿Íµ¿ ¿ÜÇüÀº ¾ðÁ¦³ª °ÇÀüÇÑ ¹ý¶ûÁú »ó¿¡ ¼³Á¤µÇ¾î¾ß ÇÏ¸ç ¿¹¹æ È®´ë°¡ ÃæºÐÇÏ¿©¾ß Çϸç, Çü¼ºµÈ ¿Íµ¿ÀÇ cave surface angle³»¿¡ Æ÷ÇԵǾîÁö´Â Ä¡¸éÀÇ ¿ÜÇüÀ» ¸»ÇÑ´Ù.
  • registration of functional form
    ±â´É ÇüÅ Àαâ
  • resistance form of cavity
    ¿Íµ¿ÀÇ ÀúÇ× ÇüÅÂ
  • retention form of cavity
    ¿Íµ¿ÀÇ À¯Áö ÇüÅÂ
  • root form endosteal implant
    Ä¡±ÙÇü °ñ³» ÀÓÇöõÆ®
  • spherical form of occlusion
    ±³ÇÕ ±¸¸é, ±³ÇÕÀÇ ±¸¸é
    Ä¡¾ÆÀÇ ¼öÆò¸é À§¿¡ Áß½ÉÀ» °¡Áø °¡»ó±¸.
  • systemic form
    Àü½Å ÇüÅÂ
  • treatment outcome form
    Ä¡·á °á°ú Æò°¡Ç¥
  • ulcerated form
    ±Ë¾ç ÇüÅÂ
    ±Ë¾çÀÇ ¸ð½À°ú ºñ½ÁÇÑ, ¹é»ö ¶Ç´Â Ȳ°¥»öÀÇ ¼¶À¯¼Ò ÀÀ±«·Î µ¤¿© ÀÖ´Â ¸ð¾ç.
  • undissociated form
    ºñÇØ¸®Çü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
active movement Movement effected by the organism itself, unaided by external influences.
(05 Mar 2000)
active mutant A mutant with overt phenotypic expression.
(05 Mar 2000)
active placebo <pharmacology> Any dummy medical treatment, originally, a medicinal preparation having no specific pharmacological activity against the patients illness or complaint given solely for the psychophysiological effects of the treatment, more recently, a dummy treatment administered to the control group in a controlled clinical trial in order that the specific and non-specific effects of the experimental treatment can be distinguished i.e., the experimental treatment must produce better results than the placebo in order to be considered effective.
(18 Nov 1997)
active principle A constituent of a drug, usually an alkaloid or glycoside, upon the presence of which the characteristic therapeutic action of the substance largely depends.
(05 Mar 2000)
active prophylaxis Use of an antigenic (immunogenic) agent to actively stimulate the immunological mechanism.
(05 Mar 2000)
active psychoanalysis Psychoanalysis in which the analyst intervenes directly and actively in the patient's life, e.g., by making prohibitions, assigning tasks.
(05 Mar 2000)
active pyruvate An intermediate formed in the oxidative decarboxylation of pyruvate.
Compare: pyruvate dehydrogenase (lipoamide).
Synonym: alpha-lactyl-thiamin pyrophosphate.
(05 Mar 2000)
active repressor A repressor that combines directly with an operator gene to repress the operator and its structural genes, thus repressing protein synthesis; active repressor may be repressed by an inducer, with resulting protein synthesis; a homeostatic mechanism for regulation of inducible enzyme systems.
(05 Mar 2000)
active site <chemistry> A specific region of an enzyme where a substrate binds and catalysis takes place (binding site).
(06 May 1997)
active splint A splint utilizing springs or elastic bands that aids in movements initiated by the patient by controlling the plane and range of motion.
Synonym: active splint, functional splint.
(05 Mar 2000)
active succinate The condensation product of succinic acid and CoA; one of the intermediates of the tricarboxylic acid cycle and a precursor in the synthesis of haem.
Synonym: active succinate, succinyl-CoA.
(05 Mar 2000)
active sulfate 3'-phosphoadenosine 5'-phosphosulfate;an intermediate in the formation of urinary ethereal sulfates, notable for containing a "high energy" sulfate bond; the 3'-OH of adenosine is replaced by -OPO3H2, the 5'-OH by -OP(O2H)-OSO3H.
Synonym: active sulfate.
Acronym: PAPS
(05 Mar 2000)
active transport <biochemistry, chemistry> Transport of ions, nutrients or other molecules into a cell against a concentration gradient, this requires the expenditure of energy through ATP hydrolysis.
(06 May 1997)
active treatment A therapeutic substance or course intended to ameliorate the basic disease problem, as opposed to supportive or palliative treatment.
Compare: causal treatment.
(05 Mar 2000)
active vasoconstriction Reduced caliber of a vessel caused by increased tonus in the smooth muscle in its walls.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á